Invivyd (NASDAQ:IVVD) Insider Sells 17,043 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 17,043 shares of Invivyd stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $14,316.12. Following the transaction, the insider directly owned 178,765 shares in the company, valued at approximately $150,162.60. The trade was a 8.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Performance

Invivyd stock traded up $0.13 during mid-day trading on Tuesday, reaching $0.87. 7,732,095 shares of the company were exchanged, compared to its average volume of 3,061,089. The business has a fifty day moving average of $0.77 and a 200 day moving average of $1.23. The firm has a market cap of $255.75 million, a P/E ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a 12-month low of $0.48 and a 12-month high of $3.07.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Sell-side analysts predict that Invivyd, Inc. will post -0.52 EPS for the current year.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Trading of Invivyd

Large investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp increased its stake in Invivyd by 9.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock valued at $139,000 after purchasing an additional 8,800 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Invivyd by 54.3% during the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after buying an additional 9,568 shares during the period. Courier Capital LLC purchased a new stake in shares of Invivyd during the fourth quarter valued at $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd during the fourth quarter valued at $27,000. Finally, DRW Securities LLC acquired a new position in shares of Invivyd in the 4th quarter valued at $27,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.